Analytical Data
-
基因名
MRPL22
- Application
-
别名
MRPL22; MRPL25; RPML25; HSPC15839S ribosomal protein L22; mitochondrial; L22mt; MRP-L22; 39S ribosomal protein L25; mitochondrial; L25mt; MRP-L25; Mitochondrial large ribosomal subunit protein uL22m
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NWU5
-
表达区间
41-206 aa
-
氨基酸序列
ISRKWEKKNK IVYPPQLPGE PRRPAEIYHC RRQIKYSKDK MWYLAKLIRG MSIDQALAQL EFNDKKGAKI IKEVLLEAQD MAVRDHNVEF RSNLYIAEST SGRGQCLKRI RYHGRGRFGI MEKVYCHYFV KLVEGPPPPP EPPKTAVAHA KEYIQQLRSR TIVHTL
-
分子量
23.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human Prss22 Protein，His
Cat：PA1000-2536
Recombinant Human GLVR1 Protein，His
Cat：PA2000-918DB
Protein Description
MRPL22, a member of the mitochondrial ribosomal protein family, plays a crucial role in the biogenesis of mitochondria and the synthesis of mitochondrial proteins. As a component of the mitochondrial ribosome, MRPL22 is essential for the proper translation of mitochondrial mRNA, which encodes key proteins involved in oxidative phosphorylation and energy production. Mutations or dysregulation of MRPL22 have been associated with various mitochondrial disorders, leading to a range of clinical manifestations, including neurodegenerative diseases, myopathies, and metabolic dysfunctions. The recombinant expression of MRPL22 is vital for investigating its structure-function relationship, understanding its role in mitochondrial dynamics, and exploring its potential as a therapeutic target. Recent advancements in protein engineering and expression systems have facilitated the production of MRPL22 in a soluble form, enabling detailed biophysical and biochemical characterization. This research not only aids in elucidating the mechanisms underlying mitochondrial pathologies but also contributes to the development of novel strategies for the treatment of related diseases. Understanding the functional properties and interaction partners of MRPL22 through recombinant technology holds promise for uncovering new insights into mitochondrial biology and its implications in human health.
